| Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome J Delaloye, T Roger, QG Steiner-Tardivel, D Le Roy, M Knaup Reymond, ... PLoS pathogens 5 (6), e1000480, 2009 | 374 | 2009 |
| Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19 CE Gómez, B Perdiguero, M Esteban Vaccines 9 (3), 243, 2021 | 222 | 2021 |
| The interferon system and vaccinia virus evasion mechanisms B Perdiguero, M Esteban Journal of Interferon & Cytokine Research 29 (9), 581-598, 2009 | 217 | 2009 |
| The evolution of poxvirus vaccines L Sánchez-Sampedro, B Perdiguero, E Mejías-Pérez, J García-Arriaza, ... Viruses 7 (4), 1726-1803, 2015 | 191 | 2015 |
| Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates BJ Flynn, K Kastenmüller, U Wille-Reece, GD Tomaras, M Alam, ... Proceedings of the National Academy of Sciences 108 (17), 7131-7136, 2011 | 164 | 2011 |
| MVA and NYVAC as vaccines against emergent infectious diseases and cancer C E Gomez, J L Najera, M Krupa, B Perdiguero, M Esteban Current gene therapy 11 (3), 189-217, 2011 | 139 | 2011 |
| Movements of vaccinia virus intracellular enveloped virions with GFP tagged to the F13L envelope protein MM Geada, I Galindo, MM Lorenzo, B Perdiguero, R Blasco Journal of General Virology 82 (11), 2747-2760, 2001 | 122 | 2001 |
| Poxvirus vectors as HIV/AIDS vaccines in humans C Elena Gomez, B Perdiguero, J García-Arriaza, M Esteban Human vaccines & immunotherapeutics 8 (9), 1192-1207, 2012 | 89 | 2012 |
| The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens CE Gómez, JL Nájera, B Perdiguero, J García-Arriaza, COS Sorzano, ... Journal of virology 85 (21), 11468-11478, 2011 | 89 | 2011 |
| Clinical applications of attenuated MVA poxvirus strain CE Gómez, B Perdiguero, J García-Arriaza, M Esteban Expert review of vaccines 12 (12), 1395-1416, 2013 | 84 | 2013 |
| Improved NYVAC-based vaccine vectors KV Kibler, CE Gomez, B Perdiguero, S Wong, T Huynh, S Holechek, ... PloS one 6 (11), e25674, 2011 | 81 | 2011 |
| Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1 … F García, JCLB de Quirós, CE Gómez, B Perdiguero, JL Nájera, ... Vaccine 29 (46), 8309-8316, 2011 | 81 | 2011 |
| Cryo X-ray nano-tomography of vaccinia virus infected cells FJ Chichón, MJ Rodríguez, E Pereiro, M Chiappi, B Perdiguero, ... Journal of structural biology 177 (2), 202-211, 2012 | 74 | 2012 |
| Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein J Falivene, MP Del Médico Zajac, MF Pascutti, AM Rodríguez, C Maeto, ... PloS one 7 (2), e32220, 2012 | 72 | 2012 |
| Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1 B Mothe, N Climent, M Plana, M Rosàs, JL Jiménez, ... Journal of Antimicrobial Chemotherapy 70 (6), 1833-1842, 2015 | 66 | 2015 |
| Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice CE Gómez, B Perdiguero, JL Nájera, COS Sorzano, V Jiménez, ... Journal of virology 86 (9), 5026-5038, 2012 | 57 | 2012 |
| Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors ED Quakkelaar, A Redeker, EK Haddad, A Harari, SM McCaughey, ... PloS one 6 (2), e16819, 2011 | 50 | 2011 |
| Head-to-head comparison of poxvirus NYVAC and ALVAC vectors expressing identical HIV-1 clade C immunogens in prime-boost combination with Env protein in nonhuman primates J García-Arriaza, B Perdiguero, J Heeney, M Seaman, DC Montefiori, ... Journal of virology 89 (16), 8525-8539, 2015 | 42 | 2015 |
| Comparison of immunogenicity in rhesus macaques of transmitted-founder, HIV-1 group M consensus, and trivalent mosaic envelope vaccines formulated as a DNA prime, NYVAC, and … SL Hulot, B Korber, EE Giorgi, N Vandergrift, KO Saunders, ... Journal of virology 89 (12), 6462-6480, 2015 | 42 | 2015 |
| Interaction between vaccinia virus extracellular virus envelope A33 and B5 glycoproteins B Perdiguero, R Blasco Journal of virology 80 (17), 8763-8777, 2006 | 41 | 2006 |
